Accessibility Menu
 
Abivax Société Anonyme logo

Abivax Société Anonyme

(NASDAQ) ABVX

Current Price$121.91
Market Cap$9.88B
Since IPO (2023)+1,402%
5 YearN/A
1 Year+1,782%
1 Month+7%

Abivax Société Anonyme Financials at a Glance

Market Cap

$9.88B

Revenue (TTM)

$10.79M

Net Income (TTM)

$458.26M

EPS (TTM)

$-5.41

P/E Ratio

-23.06

Dividend

$0.00

Beta (Volatility)

0.86 (Low)

Price

$121.91

Volume

16,178

Open

$124.72

Previous Close

$124.65

Daily Range

$121.24 - $126.50

52-Week Range

$5.59 - $148.83

ABVX: Motley Fool Moneyball Superscore

63

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Abivax Société Anonyme

Industry

Biotechnology

Employees

69

CEO

Marc M. P. de Garidel, EMBA

Headquarters

Paris, 75008, FR

ABVX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

0%

Return on Capital

-48%

Return on Assets

-58%

Earnings Yield

-4.34%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$9.88B

Shares Outstanding

79.29M

Volume

16.18K

Avg. Volume

947.43K

Financials (TTM)

Gross Profit

$1.03M

Operating Income

$240.73M

EBITDA

$239.70M

Operating Cash Flow

$155.69M

Capital Expenditure

$136.40K

Free Cash Flow

$155.83M

Cash & ST Invst.

$530.16M

Total Debt

$32.08M

Abivax Société Anonyme Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$2.02M

-186.7%

Gross Profit

$3.05M

-231.0%

Gross Margin

0.00%

N/A

Market Cap

$9.88B

N/A

Market Cap/Employee

$143.24M

N/A

Employees

69

N/A

Net Income

$222.05M

-131.8%

EBITDA

$146.11M

-58.7%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$498.08M

+145.4%

Accounts Receivable

$10.49M

-45.1%

Inventory

$0.00

N/A

Long Term Debt

$30.78M

+14.9%

Short Term Debt

$1.30M

-95.8%

Return on Assets

-57.52%

N/A

Return on Invested Capital

-48.08%

N/A

Free Cash Flow

$71.28M

+0.0%

Operating Cash Flow

$71.28M

-0.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CYTKCytokinetics, Incorporated
$77.67+4.55%
AXSMAxsome Therapeutics, Inc.
$218.83-0.63%
MDGLMadrigal Pharmaceuticals, Inc.
$515.15-3.69%
NUVLNuvalent, Inc.
$106.50+4.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.37+0.06%
RXTRackspace Technology
$4.93+0.40%
TQQQProShares Trust - ProShares UltraPro Qqq
$74.50+0.04%
OPENOpendoor Technologies
$4.96-0.07%

Questions About ABVX

What is the current price of Abivax Société Anonyme?

Abivax Société Anonyme is trading at $121.91 per share.

What is the 52-week range for Abivax Société Anonyme?

Over the past 52 weeks, Abivax Société Anonyme has traded between $5.59 and $148.83.

How much debt does Abivax Société Anonyme have?

As of the most recent reporting period, Abivax Société Anonyme reported total debt of $37.69M.

How much cash does Abivax Société Anonyme have on hand?

Abivax Société Anonyme reported $606.82M in cash and cash equivalents in its most recent financial results.

What is Abivax Société Anonyme’s dividend yield?

Abivax Société Anonyme does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.